戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tood disorder affecting 15% of patients with autoimmune hemolytic anemia.
2 dying within 3 to 5 wk from complications of autoimmune hemolytic anemia.
3 the BALB/c background, they rapidly die from autoimmune hemolytic anemia.
4 ion of autoantibodies and the development of autoimmune hemolytic anemia.
5  hemolytic anemia is the most common form of autoimmune hemolytic anemia.
6 lement may be exploited to prevent and treat autoimmune hemolytic anemia.
7 ocytes by Kupffer cells in a murine model of autoimmune hemolytic anemia.
8 emissions in patients with severe refractory autoimmune hemolytic anemia.
9 elops anti-erythrocyte Abs and is a model of autoimmune hemolytic anemia.
10      Reactive hemophagocytic syndrome (44%), autoimmune hemolytic anemia (33%), and lymphoma (22%) we
11                     One patient developed an autoimmune hemolytic anemia 4 years after transplantatio
12 tive and autoimmune disease characterized by autoimmune hemolytic anemia (AHA) and inflammatory bowel
13                                              Autoimmune hemolytic anemia (AHA) is a common complicati
14 clones recovered ex vivo from a patient with autoimmune hemolytic anemia (AIHA) and characterize thei
15  retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated
16 he role of complement in the pathogenesis of autoimmune hemolytic anemia (AIHA) has been controversia
17 tly spontaneous autoimmune diseases, such as autoimmune hemolytic anemia (AIHA) in New Zealand Black
18                                              Autoimmune hemolytic anemia (AIHA) is a disease in which
19 resulting from the deletion of IL-2 in which autoimmune hemolytic anemia (AIHA) is a prominent featur
20                                              Autoimmune hemolytic anemia (AIHA) is an uncommon entity
21                                              Autoimmune hemolytic anemia (AIHA) is the result of incr
22 ops a genetically imposed severe spontaneous autoimmune hemolytic anemia (AIHA) that is very similar
23                                           In autoimmune hemolytic anemia (AIHA), circulating red bloo
24 ond-line therapy in 23 patients with primary autoimmune hemolytic anemia (AIHA).
25 d cell (RBC) autoantibodies in patients with autoimmune hemolytic anemia (AIHA).
26             The development of warm-antibody autoimmune hemolytic anemia (also known as warm autoimmu
27 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rh
28 clonal B-cell lymphoproliferation results in autoimmune hemolytic anemia and cold-induced circulatory
29 en loss has been reported in the settings of autoimmune hemolytic anemia and transfusion of crossmatc
30 e treated similarly to those with idiopathic autoimmune hemolytic anemia, and additional therapy for
31 rplasia, autoimmune lymphocytic thyroiditis, autoimmune hemolytic anemia, and colitis.
32 oimmune disease, usually characterized by an autoimmune hemolytic anemia, and NZB genes are essential
33 plegia, injection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack of vacci
34 epitopes that emerge on erythrocytes lead to autoimmune hemolytic anemia, and the causative auto-IgM
35 is, serositis, neuropsychiatric involvement, autoimmune hemolytic anemia, anti-double-stranded DNA, a
36 Reversible posterior leukoencephalopathy and autoimmune hemolytic anemia are newly reported clinical
37                             Vasculitides and autoimmune hemolytic anemia are the two most common auto
38 eases like hereditary spherocytosis (HS) and autoimmune hemolytic anemia, but also with RBC senescenc
39               Transfusion, in the setting of autoimmune hemolytic anemia, can be a complicated and po
40 enotypes among descriptive diagnoses such as autoimmune hemolytic anemia, chronic immune thrombocytop
41          In immune thrombocytopenia and warm autoimmune hemolytic anemia, circulating immunoglobulin
42 th BALB/c mice, but which are predisposed to autoimmune hemolytic anemia, develop auto-antibodies to
43                          One patient with an autoimmune hemolytic anemia developed PML after treatmen
44 l as autoimmune complications manifesting as autoimmune hemolytic anemia, immune-mediated thrombocyto
45  children (none with serious infection), and autoimmune hemolytic anemia in two (resolved with a ster
46 isorder is cold agglutinin disease (CAD), an autoimmune hemolytic anemia in which autoantibodies (col
47 ory role of complement in the development of autoimmune hemolytic anemia is discussed.
48                      Patients with secondary autoimmune hemolytic anemia may be treated similarly to
49 essary, the therapies used for warm antibody autoimmune hemolytic anemia may be tried with less likel
50  as immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia, mouse models were used to e
51 severe refractory thrombocytopenia (n = 13), autoimmune hemolytic anemia (n = 15), and vasculitis (n
52                    ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n =
53  varies depending on whether the patient has autoimmune hemolytic anemia of warm antibody type, cold
54 yositis/dermatomyositis, systemic sclerosis, autoimmune hemolytic anemia, pernicious anemia, and anky
55 rapeutic plasma exchange in the treatment of autoimmune hemolytic anemia remains uncertain.
56 syndrome, paroxysmal cold hemoglobinuria, or autoimmune hemolytic anemia secondary to an underlying d
57            Initial therapy for warm antibody autoimmune hemolytic anemia should be corticosteroids, s
58  the transfusion management of patients with autoimmune hemolytic anemia, specifically focusing on pu
59  arthritis, immune thrombocytopenic purpura, autoimmune hemolytic anemia, systemic lupus erythematosu
60 o discovered a potential early biomarker for autoimmune hemolytic anemia that is based on different l
61 le mechanistic link between the induction of autoimmune hemolytic anemia, the reduction in naive T ce
62  and its major complications: hypersplenism, autoimmune hemolytic anemia, thrombocytopenia, and neutr
63 nic purpura (ITP), hereditary spherocytosis, autoimmune hemolytic anemia, thrombotic thrombocytopenic
64 crit level increased in 60% of patients with autoimmune hemolytic anemia undergoing successful laparo
65                                 Treatment of autoimmune hemolytic anemias varies depending on whether
66 oimmune hemolytic anemia (also known as warm autoimmune hemolytic anemia [WAHA]) in patients with bab
67  +6 and +12; the response was better in warm autoimmune hemolytic anemia (WAIHA; overall response, 10
68                      Using a murine model of autoimmune hemolytic anemia, we defined the contribution
69 hamide among patients with severe refractory autoimmune hemolytic anemia, we treated 9 patients with
70                                       Unlike autoimmune hemolytic anemia, which is characterized by a
71 tinues to be reported sporadically in severe autoimmune hemolytic anemia, with inconsistent results.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。